KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to -$174.9 million.

  • Alnylam Pharmaceuticals' Change in Accured Expenses fell 18153.67% to -$174.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $75.1 million, marking a year-over-year decrease of 1759.41%. This contributed to the annual value of $75.1 million for FY2025, which is 1759.41% down from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Change in Accured Expenses is -$174.9 million, which was down 18153.67% from $223.5 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Change in Accured Expenses high stood at $223.5 million for Q3 2025, and its period low was -$174.9 million during Q4 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Change in Accured Expenses value was $57.3 million (recorded in 2021), while the average stood at $26.4 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Change in Accured Expenses soared by 32426.31% in 2021 and then plummeted by 310117.16% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Change in Accured Expenses stood at $39.5 million in 2021, then soared by 159.78% to $102.6 million in 2022, then crashed by 137.68% to -$38.7 million in 2023, then plummeted by 60.62% to -$62.1 million in 2024, then crashed by 181.54% to -$174.9 million in 2025.
  • Its Change in Accured Expenses stands at -$174.9 million for Q4 2025, versus $223.5 million for Q3 2025 and $182.1 million for Q2 2025.